Automated quantitative breakdown of fundamental strengths between LUPIN and CIPLA.
| Financial Metric | LUPIN | CIPLA |
|---|---|---|
| Valuation Multiples | ||
| Market Capitalization | ₹95,797 Cr | ₹1,10,353 Cr |
| Price to Earnings (P/E) | 16.83 | 32.32 |
| Price to Book (P/B) | 3.18 | 3.23 |
| Profitability & Capital Efficiency | ||
| Return on Capital Employed (ROCE) | 31.14% | 15.89% |
| Return on Equity (ROE) | 16.19% | 11.12% |
| Operating Profit Margin (OPM) | 26.45% | 16.22% |
| Net Profit Margin (NPM) | 33.36% | 23.17% |
| Balance Sheet & Solvency | ||
| Debt to Equity Ratio | 0.04 | 0.00 |
| Dividend Yield | 4.38% | 6.82% |
| Historical Growth | ||
| 3-Year Sales Growth (CAGR) | 28.20% | 1.84% |
| Latest Quarter Financial Results | ||
| Quarterly Revenue (30 Jun 2026) | ₹8,217 Cr | ₹7,077 Cr |
| Quarterly Net Profit | ₹1,415 Cr | ₹789 Cr |
Sun Pharmaceutical Industries vs Cipla Limited
DRREDDY vs CIPLADr. Reddy's Laboratories vs Cipla Limited
CIPLA vs LAURUSLABSCipla Limited vs Laurus Labs
LUPIN vs SUNPHARMALupin Limited vs Sun Pharmaceutical Industries
DRREDDY vs LUPINDr. Reddy's Laboratories vs Lupin Limited
MANKIND vs CIPLAMankind Pharma vs Cipla Limited